Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021

Published on March 10, 2022

This report describes the treatment of Chagas disease using nifurtimox.

Continue reading on website
Other news

EARLY RELEASE: SARS-CoV-2 Incidence in K-12 School Districts with Mask-Required Versus Mask-Optional Policies - Arkansas, August-October 2021

March 8, 2022
This report compares COVID-19 incidence in Arkansas K-12 school districts between those with mask requirements versus those without mask requirements.

EARLY RELEASE: Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022

March 11, 2022
This report describes vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine as effective in protecting against Omicron infection among children and adolescents.